BE Biosol partners Gates Foundation to expand global access to ferric carboxymaltose to battle anaemia | Hyderabad News


BE Biosol partners Gates Foundation to expand global access to ferric carboxymaltose to battle anaemia

Hyderabad: BE Biosol Private Limited, a wholly owned subsidiary of Biological E Limited, has signed an agreement with Gates Foundation for the development of ferric carboxymaltose injection and to expand its access across multiple countries, in a move aimed at reducing the burden of iron deficiency anaemia.Ferric Carboxymaltose is used to treat iron deficiency when oral iron is ineffective or unsuitable, making affordability and supply important for health systems serving vulnerable populations. Iron deficiency anaemia affects millions globally and remains a public health concern in low- and middle-income countries, especially in Africa.Under the collaboration, the foundation will support BE Biosol in scaling up production and advancing clinical development of the intravenous iron therapy. BE Biosol will use its research and development capabilities, proprietary active pharmaceutical ingredient technology and sterile injectable manufacturing infrastructure to prepare the product for commercial availability.The agreement comes as ferric carboxymaltose markets in the United States and Europe are moving closer to generic competition.BE Biosol said its manufacturing scale and proprietary API technology position it to offer a differentiated and cost-competitive product while building a global presence.The partnership will also support BE Biosol’s efforts to strengthen clinical advancement and commercial readiness at its facilities, it added.Narender Mantena, managing director, BE Biosol, said the collaboration reflects the company’s public health commitment and confidence in its ability to develop and manufacture technologically demanding sterile formulations at competitive cost and scale.He said it also supports BE Biosol’s strategy to become a competitive contract development and manufacturing organisation across complex biologics and pharmaceutical products.The company’s manufacturing site at Shamirpet in Telangana, commissioned in 2018, has received approvals from regulatory agencies including US Food and Drug Administration, Portugal’s Infarmed, UK Medicines and Healthcare products Regulatory Agency and Brazil’s ANVISA.BE Biosol, which is developing a CDMO platform serving biopharmaceutical partners from development through commercialisation, is focused on vaccines, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), mRNA therapeutics and complex injectable products.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *